IntegriChain, the leading provider of pharma revenue optimization technology and insights, has officially announced the launch of ICyte Commercial Data Suite, which happens to be a comprehensive platform, focused on unifying operational, financial, and commercial data to drive commercial decision-making and go-to-market profitability.
According to certain reports, the stated platform arrives on the scene bearing an ability to combine enterprise data management and analytics, all for the purpose of improving both commercial decisioning and go-to-market profitability so to solve the industry’s data fragmentation, quality, and integration gaps.
More on that would reveal how ICyte Commercial Data Suite integrates information attached with CRM, market, channel, and net revenue to power commercial decisions with superior financial context. The solution offers, especially for emerging pharma manufacturers, an end-to-end data solution to let them ramp up analytics and drive data-driven commercialization quickly and easily.
Taking a deeper view of what all is included in the ICyte Commercial Data Suite, we begin from its data management capabilities, where you can come expecting a facility for data aggregation. You see, IntegriChain’s best-in-class data aggregation integrates and stewards the quality of specialty pharmacy, distributor, and patient service data, doing so through ICyte’s data quality management and patient mastering fabrics.
Next up, we must delve into the given suite’s data cloud, which is a combination of ICyte’s business intelligence (BI), artificial intelligence (AI), and reporting tools, a combination which allows manufacturers to access any first-, second- and third-party commercial data on one secure commercial data platform.
“Pharma manufacturers lack the commercial insights that help battle the headwinds of lagging net revenue performance, unprofitable growth, excessive enterprise cost, and forecast and accrual inaccuracies,” said Josh Halpern, CEO of IntegriChain. “IntegriChain was a pioneer in data aggregation, and over the past decade we’ve become a leading platform for net revenue management. Now we’ve utilized that combined experience and expertise to deliver a unique ICyte Commercial Data Suite, allowing pharma manufacturers to turn their considerable investments in commercial data into true business value for successful and profitable commercialization.”
Another detail worth a mention here is rooted in prospect of master data management. This translates to how ICyte integrates with or hosts manufacturers’ master data management system of record, thus enabling IntegriChain data stewards to align all of the commercial data assets with authoritative HCPs, payers, and HCOs.
Moving on from the data management aspect, we now must touch upon the given suite’s channel analytics that, on their part, are geared towards offering end-to-end supply chain visibility and reconciliation, forming a package enriched with segmentation across the entire care continuum.
Joining that would be an assortment of patient journey analytics. Here, ICyte brings forth AI-powered patient journey diagnostics and signaling to optimize support, as well as improve treatment initiation and adherence.
Beyond that, we have net revenue analytics coming into play. The stated feature allows for complete and real-time operational visibility into net revenue administration. It also ensures on-demand access of net revenue transactional data and key net revenue trending.
Hold on, we still have a few bits left to unpack, considering we haven’t yet touched upon the availability of sales and marketing analytics. Basically, ICyte Commercial Data Suite provides a best-in-class platform for integrated field sales reporting, commercial leadership reporting, omnichannel analytics, and integration with critical operational and compliance functions, such as incentive management and Sunshine Act reporting.
Founded in 2005, IntegriChain’s rise up the ranks stems from its ability to provide revenue optimization technology and insights for the pharma industry. The company’s solutions assortment, at the moment, includes a focus on data management, enterprise applications, consulting, and outsourcing, each one capable of empowering pharma manufacturers to achieve better financial results by connecting commercial execution to net revenue.
“With this new offering, we’ve combined the best-of-breed data science and technology across the breadth of first-, second-, and third-party commercial data, delivering analytics and insights that improve net revenue performance,” said Halpern.
